Half-year report · HY
4539.TEDINET S100X2VF
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥15.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥32.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥15.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥122m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥76m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥48m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥443m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥62m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥205m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥62m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥163m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥294m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥44m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥163m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥44m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥52.0bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥49.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥52.0bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥33.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥30.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥18.9bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥19.2bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.6bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.0bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.0bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥9.0bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.0bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.8bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.2bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥265m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥702m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥151m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥88m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥305m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥974m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥45.27 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥81.72 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.26 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 36.4% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.4% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 27
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥588m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥577m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥11m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥11m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥11m |
| Medicinereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥15.4bn |
| Medicinereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥15.4bn |
| Medicinereportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥125m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥15.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥15.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥11m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥122m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥627m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥570m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥56m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥38m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥61m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥61m |
| Medicinereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.1bn |
| Medicinereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.1bn |
| Medicinereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4m |
| Medicinereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥38m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥15.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥15.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥61m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥76m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 540
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from sales of investment securities inv cf | Prior1InterimDuration | － | JPY |
| Proceeds from sales of investment securities inv cf | InterimDuration | 205000000 | JPY |
| Proceeds from collection of guarantee deposits inv cf | Prior1InterimDuration | 1000000 | JPY |
| Proceeds from collection of guarantee deposits inv cf | InterimDuration | 2000000 | JPY |
| Other net inv cf | Prior1InterimDuration | 0 | JPY |
| Other net inv cf | InterimDuration | -0 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration | -88000000 | JPY |
| Net cash provided by used in investment activities | InterimDuration | -151000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1InterimDuration | -266000000 | JPY |
| Net increase decrease in short term loans payable fin cf | InterimDuration | 84000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1InterimDuration | 2850000000 | JPY |
| Proceeds from long term loans payable fin cf | InterimDuration | 1850000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -1382000000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -1650000000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -182000000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -182000000 | JPY |
| Other net fin cf | Prior1InterimDuration | -45000000 | JPY |
| Other net fin cf | InterimDuration | -100000000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | 974000000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | 1000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | 16000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | -45000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | 1604000000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | 1969000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 9200000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 7021000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 10805000000 | JPY |
| Cash and cash equivalents | InterimInstant | 8991000000 | JPY |
| Advertising expenses sga | Prior1InterimDuration | 33000000 | JPY |
| Advertising expenses sga | InterimDuration | 34000000 | JPY |
| Traveling and transportation expenses sga | Prior1InterimDuration | 160000000 | JPY |
| Traveling and transportation expenses sga | InterimDuration | 161000000 | JPY |
| Salaries sga | Prior1InterimDuration | 1256000000 | JPY |
| Salaries sga | InterimDuration | 1299000000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 37000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 32000000 | JPY |
| Commission fee sga | Prior1InterimDuration | 620000000 | JPY |
| Commission fee sga | InterimDuration | 651000000 | JPY |
| Research and development expenses sga | Prior1InterimDuration | 1160000000 | JPY |
| Research and development expenses sga | InterimDuration | 1007000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00957-000MedicineReportableSegmentsMember | 15055000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 570000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 15626000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 15626000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00957-000MedicineReportableSegmentsMember | 4000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 56000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 61000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -61000000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |